Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Epidemiological Burden of Hepatitis Delta Virus in the United States

Epidemiological Burden of Hepatitis Delta Virus in the United States

Authors: Marlowe EM, Swanson BE, Realegeno SE, Meyer WA 3rd, Gish R, Kagan RMS

Citation: J Viral Hepat. 2025 Jun;32(6):e70029. doi: 10.1111/jvh.70029. PMID: 40298139.

Specialties: Infectious disease

Download key summary

Related content

Publication
HDV RNA assays: performance characteristics, clinical utility and challenges
Conference Presentation
Seroprevalence of Hepatitis D Virus (HDV) antibodies in patient specimens with detectable HDV RNA
Conference Presentation
Estimated National Hepatitis C Prevalence using Residual Sera from a National Commercial Laboratory – United States, November 2023–September 2024
Publication
Hepatitis C Virus Testing During Pregnancy Following Universal Screening Recommendations
Publication
Social Determinants of Hepatitis C Virus Infection in the United States, 2016–2021

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.